Get the Stockscreener App
40.12
3.64%
1.41
After Hours:
40.06
-0.06
-0.15%
Liquidia Corp stock is traded at $40.12, with a volume of 942.37K.
It is up +3.64% in the last 24 hours and up +9.44% over the past month.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
See More
Previous Close:
$38.71
Open:
$38.92
24h Volume:
942.37K
Relative Volume:
0.54
Market Cap:
$3.54B
Revenue:
$158.32M
Net Income/Loss:
$-68.92M
P/E Ratio:
-48.24
EPS:
-0.8317
Net Cash Flow:
$-40.02M
1W Performance:
+5.05%
1M Performance:
+9.44%
6M Performance:
+73.23%
1Y Performance:
+195.00%
1-Day Range:
$38.92
$40.42
1-Week Range:
$37.55
$40.76
52-Week Range:
$11.85
$46.67
Liquidia Corp Stock (LQDA) Company Profile
Name
Liquidia Corp
Sector
Phone
919.328.4400
Address
419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
Compare LQDA vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LQDA
Liquidia Corp
|
40.12 | 3.41B | 158.32M | -68.92M | -40.02M | -0.8317 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 56.39B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
120.76 | 50.93B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.66 | 43.19B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.61 | 36.99B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
577.58 | 25.36B | 3.18B | 1.33B | 1.04B | 27.90 |
Liquidia Corp Stock (LQDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-15-25 | Resumed | Jefferies | Buy |
| May-19-25 | Downgrade | Oppenheimer | Perform → Underperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-16-24 | Initiated | Raymond James | Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Perform |
| Jan-05-24 | Reiterated | Needham | Buy |
| Sep-19-22 | Resumed | Wedbush | Underperform |
| Sep-01-22 | Downgrade | Wedbush | Neutral → Underperform |
| Jul-22-22 | Initiated | Ladenburg Thalmann | Buy |
| May-31-22 | Initiated | BTIG Research | Buy |
| May-26-22 | Initiated | BofA Securities | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Nov-20-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-05-18 | Initiated | Wedbush | Outperform |
| Aug-20-18 | Initiated | Jefferies | Buy |
| Aug-20-18 | Initiated | Needham | Buy |
View All
Liquidia Corp Stock (LQDA) Latest News
Insider Selling: Liquidia (NASDAQ:LQDA) General Counsel Sells 13,692 Shares of Stock - MarketBeat
Insider Selling: Liquidia (NASDAQ:LQDA) CEO Sells 32,744 Shares of Stock - MarketBeat
Liquidia (NASDAQ:LQDA) CAO Sells $195,725.37 in Stock - MarketBeat
Liquidia CFO Kaseta sells $1.68 million in LQDA stock By Investing.com - Investing.com India
Liquidia Corp CCO Moomaw sells $404k in shares By Investing.com - Investing.com India
Liquidia corp (LQDA) CBO Adair sells $280k in shares - Investing.com
Liquidia Corp CEO Jeffs sells $2.1m in shares - Investing.com
Liquidia Corp CHRO Krepp sells $174852 in LQDA stock - Investing.com
Liquidia Insider Sold Shares Worth $280,139, According to a Recent SEC Filing - marketscreener.com
Liquidia Insider Sold Shares Worth $404,402, According to a Recent SEC Filing - marketscreener.com
Liquidia Corp CCO Moomaw sells $404k in shares - Investing.com
Liquidia’s chief accounting officer Boyle sells $195k in LQDA stock - Investing.com
Liquidia (NASDAQ: LQDA) CCO sells shares to cover tax obligations - Stock Titan
Liquidia (LQDA) CBO logs tax-cover share sale after RSU, PSU vesting - Stock Titan
Liquidia (LQDA) CAO sells 5,101 shares after PSU exercise - Stock Titan
Liquidia (NASDAQ: LQDA) CFO reports option exercises and share sales - Stock Titan
Liquidia (NASDAQ: LQDA) CHRO sells shares, exercises PSUs under plan - Stock Titan
Liquidia Corp (LQDA) CMO sells 9,220 shares under 10b5-1 plan - Stock Titan
Liquidia (LQDA) CEO sells 54,177 shares after PSU conversions - Stock Titan
Option exercise and 10b5-1 sales reported for LQDA (NASDAQ: LQDA) - Stock Titan
Liquidia Corp stock (US53634H1077): Is the picture now shifting on inhaled therapy execution? - AD HOC NEWS
Liquidia (NASDAQ:LQDA) CEO Sells $1,003,000.00 in Stock - MarketBeat
Liquidia CFO Kaseta sells $5.3m in LQDA stock By Investing.com - Investing.com South Africa
Liquidia CEO Jeffs sells $1m in LQDA stock By Investing.com - Investing.com Australia
Liquidia CEO Jeffs sells $1m in LQDA stock - Investing.com
Liquidia (LQDA) CEO sells 25,000 shares under Rule 10b5-1 plan - Stock Titan
Liquidia (LQDA) CFO Kaseta exercises options and sells 133,789 shares - Stock Titan
Tudor Investment Corp ET AL Makes New Investment in Liquidia Corporation $LQDA - MarketBeat
Liquidia Corp (LQDA) counsel sells shares to cover equity award taxes - Stock Titan
Aug Macro: Whats the MACD signal for Liquidia Corporation2026 Earnings & Detailed Earnings Play Alerts - baoquankhu1.vn
Serendipity Biopharma (LQDA) reports 25,000-share 10b5-1 sale on 04/09/2026 - Stock Titan
[144] Liquidia Corp SEC Filing - Stock Titan
Serendipity Biopharma (LQDA) files Form 144; 25,000-share resale noted - Stock Titan
Rule 144: 133,789-share option exercise (LQDA) reported to SEC - Stock Titan
Liquidia Corp (LQDA) Trading 3.65% Higher on Apr 9 - GuruFocus
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Liquidia Corporation to Participate in Upcoming Investor Conferences - The Manila Times
Liquidia CEO to give business update in an April 15 webcast - Stock Titan
Liquidia Corp Chairman Sells Shares: Transaction Details & AnalysisNews and Statistics - IndexBox
Liquidia's Chairman Sold Company Shares Worth $2.5 Million. Should Investors Avoid the Stock? - The Motley Fool
LQDA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Liquidia Corporation (LQDA) stock price, news, quote and history - Yahoo Finance UK
All eyes on Liquidia earnings as biotech eyes profitability - Investing.com
Does Liquidia Corporation (LQDA) Have the Potential to Rally 34.47% as Wall Street Analysts Expect? - Yahoo Finance
Liquidia Corp (NASDAQ:LQDA) Presents a High-Growth Momentum and Technical Setup - ChartMill
LQDA Stock Price, Quote & Chart | LIQUIDIA CORP (NASDAQ:LQDA) - ChartMill
Should Insider Stock Sale and Analyst Optimism Around Pulmonary Drugs Require Action From Liquidia (LQDA) Investors? - Yahoo Finance
Wells Fargo Lifts PT on Liquidia Corporation (LQDA) to $51 From $44 – Here’s Why - Insider Monkey
Liquidia corp director Bloch sells $2.53 million in stock By Investing.com - Investing.com India
Liquidia corp director Bloch sells $2.53 million in stock - investing.com
Venture fund tied to Liquidia (LQDA) trims 70K shares - Stock Titan
Liquidia Corp Stock (LQDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):